SkyCell and Validaide Partner to Revolutionize Pharmaceutical Supply Chains
We are excited to announce our partnership with Validaide, a leading platform in lane risk assessment, to improve decision-making and enhance lane risk assessments for pharmaceutical companies. This collaboration marks a significant step towards transforming the pharmaceutical supply chain, leveraging AI and data analytics to drive efficiency and sustainability.
The pharmaceutical industry loses approximately $35 billion annually due to failures in temperature-controlled logistics. The partnership aims to address these challenges by allowing companies to make data-driven routing decisions, streamline lane risk assessments, and accelerate lane approvals for critical shipments, ultimately helping pharmaceutical companies make better supply chain decisions.
Integrating SkyMind with Validaide for Superior Decision-Making
The partnership will see SkyMind — SkyCell‘s supply chain software platform — integrate with Validaide’s lane risk assessment and ground handling data, allowing pharma companies to make better decisions based on risk, cost, and carbon emissions. SkyMind’s CO2e software DECARBONIZE is based on the Massachusetts Institute of Technology (MIT) latest research and methodology. The DECARBONIZE software allows the comparison of one-way versus reusable packaging options, allowing companies to minimize their environmental impact while making informed decisions. With this collaboration, Validaide’s platform will be enhanced to make lane risk assessments and CO₂e comparisons with different packaging at the same time.
Enhancing Operational Control and Efficiency
In our commitment to innovation, we launched SkyMind earlier this year. This AI-powered learning system enhances operational control and saves costs by streamlining processes, maximizing efficiency, minimizing unnecessary expenses, and reducing CO2 emissions. Validaide’s network includes over 1,300 companies, contributing data to its global platform for healthcare and pharma shipments. This extensive quantitative operational data, encompassing logistics suppliers’ handling capabilities, complements SkyMind’s qualitative operational data — enhancing decision-making for pharmaceutical companies during shipments.
“SkyCell’s vision for pharma has always been zero loss and zero CO₂ emissions for the pharma supply chain. Technology is crucial for decision-makers to reduce costs, risks, and CO₂ emissions in pharma supply chains."
“Collaboration among stakeholders and technology providers is equally important. Our partnership with Validaide is a significant step forward, empowering pharmaceutical companies to take greater control of their supply chains.”
“Our longstanding relationship with SkyCell has been marked by shared goals."
“This next step in our journey together will allow us to combine our qualitative operational data with SkyMind’s quantitative data — creating a comprehensive solution for the pharma industry. Together, we look forward to helping our customers make better, more informed supply chain decisions.”
For more details on how SkyMind is revolutionizing the pharmaceutical supply chain, visit SkyMind.
News & Stories
SkyCell closes US$116 million Series D
In a significant development, SkyCell has secured a $57 million funding round in partnership with Catalyst, M&G Investments' $6 billion...
SkyCell and Ivoclar Group: Pioneering Sustainability in Reverse Logistics
In a groundbreaking move towards sustainability, SkyCell have forged a strategic partnership with Ivoclar Group, a prominent dental and medical...
SkyCell Fourth Annual Sustainability Report is now available
Dive into SkyCell's groundbreaking journey towards zero medicine loss and zero CO₂ emissions with our fourth Annual Sustainability Report. Read...